Dana-Farber study finds adding drug to standard chemotherapy provides no survival benefit for older lung cancer patients
- Posted: April 18, 2012
Adding the drug bevacizumab (Avastin) to the standard chemotherapy regimen for non-small cell lung cancer – an approach approved by the FDA in 2006 – did not lead to significantly increase survival rates for patients over the age of 65 enrolled in Medicare, a new study by Dana-Farber Cancer Institute researchers has found. The study is published in the April 18 Journal of the American Medical Association, a theme issue on comparative effectiveness research.
Among the research institutions NCI funds across the United States, it currently designates 66 as Cancer Centers. Largely based in research universities, these facilities are home to many of the NCI-supported scientists who conduct a wide range of intense, laboratory research into cancer’s origins and development. The Cancer Centers Program also focuses on trans-disciplinary research, including population science and clinical research. The centers’ research results are often at the forefront of studies in the cancer field.